AstraZeneca Pharma India has reported results for third quarter ended December 31, 2012.
The company has reported a net loss of Rs 17.70 crore for the quarter as compared to a net profit of Rs 14.94 crore for the same quarter in the previous year. Total income of the company has decreased by 32.15% at Rs 105.16 crore for quarter under review as compared to Rs 154.99 crore for the quarter ended December 31, 2011.
AstraZeneca operates through two entities, AstraZeneca Pharma India and AstraZeneca India in the country.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.00 |
| Dr. Reddys Lab | 1232.25 |
| Cipla | 1228.90 |
| Zydus Lifesciences | 936.35 |
| Lupin | 2328.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: